Moderna’s mNEXSPIKE Trials Lacked a Placebo Group
The FDA approval of Moderna’s mNEXSPIKE COVID-19 vaccine, announced on May 31, 2025, was based on a benefit-risk assessment specifically for adults aged 65 and older and individuals aged 12 to 64 with at least one underlying risk factor for severe COVID-19, as defined by the CDC. Below are the key benefits that were determined…
